Risk of Fractures and Falls during and after 5-α Reductase Inhibitor Use: A Nationwide Cohort Study.

Drug exposure in register-based research-An expert-opinion based evaluation of methods. PLoS One (2017) 0.75

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79

Risk factors for falls among elderly persons living in the community. N Engl J Med (1988) 19.23

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25

The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med (1985) 8.55

The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol (2009) 7.62

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med (1998) 6.44

Incidence and mortality of hip fractures in the United States. JAMA (2009) 6.05

Risk factors for recurrent nonsyncopal falls. A prospective study. JAMA (1989) 5.93

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol (2013) 4.89

High prevalence of benign prostatic hypertrophy in the community. Lancet (1991) 4.60

Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med (2010) 4.24

Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. JAMA (2012) 3.71

Reducing bias through directed acyclic graphs. BMC Med Res Methodol (2008) 3.67

Shifting the focus in fracture prevention from osteoporosis to falls. BMJ (2008) 3.27

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology (2002) 2.94

Testosterone and estradiol among older men. J Clin Endocrinol Metab (2005) 2.63

Causal directed acyclic graphs and the direction of unmeasured confounding bias. Epidemiology (2008) 2.60

Risks and benefits of testosterone therapy in older men. Nat Rev Endocrinol (2013) 2.47

Older men with low serum estradiol and high serum SHBG have an increased risk of fractures. J Bone Miner Res (2008) 2.44

Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab (2004) 2.39

Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res (2006) 1.91

Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest (1993) 1.88

Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol (2004) 1.73

Endogenous testosterone levels, physical performance, and fall risk in older men. Arch Intern Med (2006) 1.72

Human osteoblast-like cells express predominantly steroid 5alpha-reductase type 1. J Clin Endocrinol Metab (2002) 1.62

Associations between the metabolic syndrome and bone health in older men and women: the Rancho Bernardo Study. Osteoporos Int (2007) 1.61

Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA (2008) 1.57

Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab (1997) 1.54

The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab (2007) 1.53

The effects of serum testosterone, estradiol, and sex hormone binding globulin levels on fracture risk in older men. J Clin Endocrinol Metab (2009) 1.52

Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab (1992) 1.51

The burden of hospitalised fractures in Sweden. Osteoporos Int (2004) 1.41

The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol (Oxf) (2005) 1.41

Longitudinal changes in peak urinary flow rates in a community based cohort. J Urol (2000) 1.34

Endogenous sex hormones and incident fracture risk in older men: the Dubbo Osteoporosis Epidemiology Study. Arch Intern Med (2008) 1.29

Falls among frail older people in residential care. Scand J Public Health (2002) 1.20

PCBaSe Sweden: a register-based resource for prostate cancer research. Scand J Urol Nephrol (2009) 1.17

Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase. J Clin Invest (1992) 1.15

Hip fractures, nocturia, and nocturnal polyuria in the elderly. Arch Gerontol Geriatr (2006) 1.08

Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol (2010) 1.07

The source of plasma dihydrotestosterone in man. J Clin Invest (1971) 1.05

Use of alpha-blockers and the risk of hip/femur fractures. J Intern Med (2003) 0.98

Bone mineral density in the complete androgen insensitivity and 5alpha-reductase-2 deficiency syndromes. J Clin Endocrinol Metab (2006) 0.95

Nocturia is an age-independent risk factor for hip-fractures in men. Neurourol Urodyn (2009) 0.94

Male osteoporosis. Endocrinol Metab Clin North Am (2012) 0.92

Preventing falls: how to identify risk factors, reduce complications. Geriatrics (1996) 0.92

Testosterone but not estradiol level is positively related to muscle strength and physical performance independent of muscle mass: a cross-sectional study in 1489 older men. Eur J Endocrinol (2011) 0.89

Metabolic syndrome and physical performance in elderly men: the osteoporotic fractures in men study. J Am Geriatr Soc (2011) 0.88

The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial. J Urol (2002) 0.85

Sex steroid metabolism in the regulation of bone health in men. J Steroid Biochem Mol Biol (2010) 0.85

Impact of hip fracture on mortality: a cohort study in hip fracture discordant identical twins. J Bone Miner Res (2014) 0.84

Risk of fractures associated with treatment for benign prostate hyperplasia in men. Osteoporos Int (2010) 0.84

Estimation of the lifetime risk of hip fracture for women and men in Canada. Osteoporos Int (2011) 0.83

The association of concurrent vitamin D and sex hormone deficiency with bone loss and fracture risk in older men: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res (2012) 0.83

The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol (2008) 0.83

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU Int (2011) 0.81

Effect of finasteride on human testicular steroidogenesis. J Androl (1997) 0.76

Dihydrotestosterone is a determinant of calcaneal bone mineral density in men. J Steroid Biochem Mol Biol (2009) 0.76

Fathering of dizygotic twins and risk of prostate cancer: nationwide, population-based case-control study. PLoS One (2014) 0.75